David said gross margin was 82.1% for 2025 and 81% in the fourth quarter. He attributed the year’s results to inventory reserves booked during the year that he said would not recur, as well as a continuing product-mix impact tied to revenue-sharing arrangements for newer products.Cary said the company grew about 11% in 2025 despite disruptions, and expects 12% to 19% growth in 2026. Finance leader David added that Avita has historically grown at a compound annual growth rate of about 32% , and said manageme ...

Performance in Q4 was characterized as a period of 'control' rather than acceleration, focusing on establishing a predictable and repeatable operating model. The company successfully resolved significant reimbursement uncertainty, with six of seven Medicare Administrative Contractors (MACs) now publishing payment rates for ReCell. Commercial strategy has been refined to prioritize utilization and repeat use within approximately 200 core burn and trauma centers rather than aggressive new account acquis ...

Core Insights - The company is experiencing a normalization in the utilization of its products, particularly ReCell, as reimbursement clarity improves, which is crucial for driving growth [1][2][3] - The fourth quarter of 2025 showed revenue of $17.6 million, with a full-year revenue of approximately $71.6 million, reflecting an 11% growth over 2024 [3][11] - The company expects full-year revenue for 2026 to be between $80 million and $85 million, indicating a growth of approximately 12% to 19% over 2025 [10][11] Revenue and Financial Performance - The fourth quarter revenue of $17.6 million was consistent with revised expectations, while the full-year revenue of $71.6 million marked a consecutive year of growth despite reimbursement challenges [11][12] - Gross margin for the full year was 82.1%, down from 85.8% in 2024, attributed to product mix and inventory reserves [11][12] - Operating expenses in the fourth quarter were $24.7 million, down 5% year-over-year, primarily due to reduced sales and marketing expenses [13][14] Product Utilization and Strategy - The company is focusing on increasing adoption and repeated use of its products—ReCell, CoHiliX, and PermeDerm—within core burn and trauma centers, which account for roughly 90% of revenue [1][5] - ReCell remains the foundation of the business, supported by clinical evidence demonstrating faster healing and improved outcomes [6][7] - The company is transitioning from a ReCell-only strategy to a multiproduct acute wound care platform, which is expected to enhance revenue per patient opportunities [7] Reimbursement and Market Dynamics - Six of the seven Medicare Administrative Contractors (MACs) have published payment rates for ReCell procedures, alleviating previous reimbursement uncertainties [2][25] - The company is actively engaging with the remaining MAC to ensure reimbursement clarity and is optimistic about future developments [25][26] - The focus on establishing a disciplined operating model and improved visibility into cash use is expected to support execution and growth [4][14] Future Outlook - The company aims to maintain disciplined control of operating costs while supporting revenue growth with a stable cost structure [16][17] - The refinancing of debt through a new credit facility is designed to reduce operational friction and support execution [9][15] - The strategy for 2026 includes a commitment to clear reporting and execution, with a focus on delivering on established milestones [18]

Company Overview - AVITA Medical, Inc. (NASDAQ:RCEL) is a regenerative medicine company focused on developing and commercializing innovative therapeutic solutions for complex wound and tissue repair [4] Financial Performance - The company has guided for FY26 revenue of $80 million to $85 million, an increase from $71.6 million in FY24, indicating a positive growth outlook [3] - Recent debt refinancing has alleviated near-term liquidity concerns, contributing to a healthier balance sheet [1] Strategic Focus - Management emphasized that the past year was dedicated to stabilizing revenue, advancing the clinical pipeline, and improving financial flexibility, laying the groundwork for future growth [3] - AVITA Medical is transitioning into a phase of execution-led growth, supported by upcoming clinical and commercial milestones [3][4] Analyst Insights - Lake Street raised its price target on AVITA Medical to $3.50 from $3 while maintaining a Hold rating, indicating cautious optimism about the company's future performance [1]

Core Insights - AVITA Medical presented data from 19 scientific abstracts at the 2026 Boswick Burn & Wound Symposium, showcasing the integrated use of its technologies RECELL, PermeaDerm, and Cohealyx in wound care [1][2][3] Group 1: Integrated Use of Technologies - The first surgeon-reported experience integrating RECELL, PermeaDerm, and Cohealyx was highlighted, demonstrating reduced need for painful dressing changes and avoiding long-distance follow-ups [3] - This integrated approach is particularly beneficial for rural and community hospitals with limited access to specialized burn services [3] Group 2: Clinical Findings - Initial findings from multicenter clinical trials on PermeaDerm and Cohealyx were presented, with full results expected in 2026 [4] - PermeaDerm showed early blood vessel growth and organized tissue formation without increased inflammation compared to traditional human skin for temporary coverage [5] - Cohealyx demonstrated cellular infiltration and early blood vessel formation within two weeks, preparing the wound for skin grafting without complications [6] Group 3: RECELL Evidence and Benefits - A systematic review of 27 peer-reviewed studies reinforced the benefits of RECELL, showing consistent trends in healing, reduced complications, and shorter hospital stays [7][10] - In older burn patients, adding RECELL to standard skin grafting resulted in nearly 16 days shorter hospital stays and fewer graft failures [9] - Patients treated with RECELL for deep partial-thickness burns spent about one-third less time in the hospital compared to traditional grafting methods [9] Group 4: Practical Applications - Surgeons are demonstrating how the staged use of AVITA Medical's advanced wound care technologies can improve healing and help hospitals manage limited resources [11]

Core Insights - AVITA Medical, Inc. announced preliminary financial results for Q4 and fiscal year 2025, along with an outlook for fiscal year 2026, highlighting a shift from stabilization to growth execution [1][2] Financial Performance - Total net revenues for Q4 2025 were approximately $17.6 million, a decrease from $18.4 million in Q4 2024 [6] - Total revenues for the full year 2025 were approximately $71.6 million, an increase of about 11% compared to $64.3 million in 2024, aligning with the company's revised revenue guidance [6] - Full year 2026 revenue is expected to be in the range of approximately $80 to $85 million, representing growth of approximately 12% to 19% compared to 2025 [6] Capital Structure and Financing - The company closed a five-year credit facility with Perceptive Advisors, providing up to $60 million in capital, with an initial funding of $50 million [2][4] - The proceeds from the credit facility will be used to repay outstanding debt and support the growth of the acute wound care portfolio [2][4] - The new credit facility includes trailing twelve-month (TTM) revenue covenants, with an initial TTM revenue covenant set at $68.5 million for Q1 2026 and $73 million for the full year 2026 [3] Clinical and Commercial Developments - The Cohealyx-I study is fully enrolled, and the PermeaDerm-I study has surpassed 75% enrollment as of December 2025, with data expected later in 2026 [6] - The company is positioned to leverage its differentiated position in acute wound care for value creation through commercial execution and clinical advancement [4]

Core Insights - AVITA Medical, Inc. has appointed Joe Woody as a new non-executive Director, while Lou Panaccio has retired after serving as Chairman for over a decade [1][7] Company Leadership Changes - Joe Woody brings over two decades of leadership experience in the medical technology sector, having previously served as CEO of Avanos Medical and President and CEO of Acelity Holdings [2] - Lou Panaccio has been recognized for his significant contributions to the company's commercial and operational strategy during his tenure [2][3] Company Overview - AVITA Medical specializes in therapeutic acute wound care, focusing on innovative solutions that optimize wound healing and accelerate patient recovery [4] - The company's flagship product, the RECELL System, is FDA-approved for treating thermal burn and trauma wounds, utilizing a patient's own skin to create Spray-On Skin™ Cells [4] - In addition to RECELL, AVITA holds exclusive rights to market and distribute PermeaDerm and Cohealyx, both of which are advanced wound care products [4] International Market Presence - The RECELL System is also approved in international markets for a variety of applications, including thermal burn and trauma wounds, with regulatory clearances in Europe, Australia, and Japan [5]

Core Insights - AVITA Medical, Inc. is a leading company in therapeutic acute wound care, focusing on innovative solutions for wound healing [3][4] - The CEO, Cary Vance, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 [1] - The RECELL System is a key product that utilizes a patient's own skin to create Spray-On Skin™ Cells, enhancing clinical outcomes [3] Company Overview - AVITA Medical specializes in technologies that accelerate patient recovery from wounds [3] - The RECELL System is FDA-approved for treating thermal burn and trauma wounds, and is also recognized in international markets [4] - The company holds exclusive rights to market and distribute PermeaDerm and Cohealyx™, which are additional wound care products [3][4] Presentation Details - A live audio webcast of the upcoming presentation will be available on AVITA Medical's website [2] - A replay of the webcast will be accessible after the event concludes [2]

Core Viewpoint - AVITA Medical, Inc. will present at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, at 8:30 a.m. EST, and management will be available for one-on-one meetings with registered investors [1]. Company Overview - AVITA Medical is a leading therapeutic acute wound care company focused on delivering transformative solutions to optimize wound healing and accelerate patient recovery [3]. - The company's flagship product, the RECELL System, is FDA-approved for treating thermal burn and trauma wounds, utilizing the patient's own skin to create Spray-On Skin™ Cells for improved clinical outcomes [3]. - In the U.S., AVITA Medical holds exclusive rights to manufacture and market PermeaDerm, a biosynthetic wound matrix, and Cohealyx™, a collagen-based dermal matrix [3]. International Market Presence - The RECELL System is approved for promoting skin healing in various applications, including thermal burn and trauma wounds, with regulatory clearances in Europe, Australia, and Japan (excluding RECELL GO) [4].

Core Insights - AVITA Medical reported a commercial revenue of $17.1 million for Q3 2025, a 13% decrease from $19.5 million in Q3 2024, primarily due to reimbursement challenges [6][10] - The company expects full-year revenue for 2025 to be between $70 million and $74 million, down from previous guidance of $76 million to $81 million [16] - AVITA Medical's cash management improved, with net cash use decreasing to $6.2 million in Q3 from $10.1 million in Q2 2025 [9][15] Financial Results - Commercial revenue for Q3 2025 was $17.1 million, a decrease of $2.5 million or 13% compared to the same period in 2024 [6][10] - Operating expenses decreased by 24% to $23.0 million, down from $30.2 million in Q3 2024, reflecting cost management strategies [12][9] - Net loss improved to $13.2 million, or $0.46 per share, compared to a net loss of $16.2 million, or $0.62 per share, in Q3 2024 [14] Other Quarterly Milestones - The company is focusing on approximately 200 key U.S. burn and trauma centers, targeting an addressable market of roughly $1.3 billion [3][8] - AVITA Medical received CE Mark approval for RECELL GO® in September, allowing for commercialization in Europe, starting with Germany, Italy, and the UK [5] - The reimbursement environment for RECELL has normalized, with all seven Medicare Administrative Contractors confirming payment rates [4] Clinical and Regulatory Milestones - RECELL demonstrated its effectiveness in achieving wound closure with less donor skin and faster healing, supported by data from over 8,000 patients [7] - Real-world data indicated a 36% reduction in hospital stay length and approximately $42,000 in cost savings per patient compared to traditional methods for treating second-degree burns [7] Portfolio Execution - AVITA Medical's strategy focuses on an integrated portfolio of RECELL, Cohealyx, and PermeaDerm, aiming for disciplined growth in the acute wound care market [8] - The company currently serves about 5% of the $1.3 billion addressable market, indicating significant growth potential [8]